These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 20466604)

  • 41. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. YWHAE promotes proliferation, metastasis, and chemoresistance in breast cancer cells.
    Yang YF; Lee YC; Wang YY; Wang CH; Hou MF; Yuan SF
    Kaohsiung J Med Sci; 2019 Jul; 35(7):408-416. PubMed ID: 31001932
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The use of microarray technology in the management of breast cancer.
    Pusztai L
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):193-4, 197. PubMed ID: 17519880
    [No Abstract]   [Full Text] [Related]  

  • 44. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
    Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
    Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breast tumor subgroups reveal diverse clinical prognostic power.
    Liu Z; Zhang XS; Zhang S
    Sci Rep; 2014 Feb; 4():4002. PubMed ID: 24499868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Predictive markers in breast cancer treatment--focusing on a recent topic "basal-like breast cancer"].
    Koike A; Ohta T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():285-90. PubMed ID: 17682168
    [No Abstract]   [Full Text] [Related]  

  • 47. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 48. Are current development programs realising the full potential of new agents?
    Lønning PE
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S23. PubMed ID: 21172086
    [No Abstract]   [Full Text] [Related]  

  • 49. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration.
    Triulzi T; De Cecco L; Sandri M; Prat A; Giussani M; Paolini B; Carcangiu ML; Canevari S; Bottini A; Balsari A; Menard S; Generali D; Campiglio M; Di Cosimo S; Tagliabue E
    Oncotarget; 2015 Sep; 6(29):28173-82. PubMed ID: 26334217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
    Zelnak AB; Wisinski KB
    Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
    Pegram M; Perez EA; Piccart M; Spector N
    Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S131-41. PubMed ID: 18777952
    [No Abstract]   [Full Text] [Related]  

  • 52. Identifying responders to trastuzumab therapy in breast cancer.
    Brügmann A; Sorensen BS
    Future Oncol; 2011 Jun; 7(6):767-73. PubMed ID: 21675839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The clinical relevance of the overexpression of HER-2 in breast cancer].
    Khosravi Shahi P; Pérez Manga G
    An Med Interna; 2006 Mar; 23(3):103-4. PubMed ID: 16737428
    [No Abstract]   [Full Text] [Related]  

  • 54. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.
    Elizalde PV; Cordo Russo RI; Chervo MF; Schillaci R
    Endocr Relat Cancer; 2016 Dec; 23(12):T243-T257. PubMed ID: 27765799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
    Chanrion M; Negre V; Fontaine H; Salvetat N; Bibeau F; Mac Grogan G; Mauriac L; Katsaros D; Molina F; Theillet C; Darbon JM
    Clin Cancer Res; 2008 Mar; 14(6):1744-52. PubMed ID: 18347175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 57. "Build quality in"--HER2 testing in the real world.
    Zujewski JA
    J Natl Cancer Inst; 2002 Jun; 94(11):788-9. PubMed ID: 12048261
    [No Abstract]   [Full Text] [Related]  

  • 58. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.